Intercept Pharmaceuticals Inc Enterprise value
What is the Enterprise value of Intercept Pharmaceuticals Inc?
The Enterprise value of Intercept Pharmaceuticals Inc is $353.67M
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Companies with enterprise value similar to Intercept Pharmaceuticals Inc
- Think Childcare has Enterprise value of $353.06M
- Northern Star Acquisition has Enterprise value of $353.37M
- Apollo Future Mobility has Enterprise value of $353.40M
- Force Motors has Enterprise value of $353.41M
- Sherritt International has Enterprise value of $353.53M
- Shanthi Gears has Enterprise value of $353.57M
- Intercept Pharmaceuticals Inc has Enterprise value of $353.67M
- Koenig & Bauer AG has Enterprise value of $353.75M
- 15068 has Enterprise value of $354.10M
- Lilis has Enterprise value of $354.15M
- BF Utilities has Enterprise value of $354.38M
- American Vanguard has Enterprise value of $354.50M
- Hyve Plc has Enterprise value of $354.52M